A protective bivalent vaccine against Rift Valley fever and bluetongue

Eva Calvo-Pinilla(The Pirbright Institute), Javier Ortego(Consejo Superior de Investigaciones Científicas)

npj Vaccines

July 30, 2020

10.1038/s41541-020-00218-y

Cited by 35

Related Papers

Recombinant vaccines against bluetongue virus

|Virus Research|2013|51

Ns1 Is a Key Protein in the Vaccine Composition to Protect Ifnar(−/−) Mice against Infection with Multiple Serotypes of African Horse Sickness Virus

|PLoS ONE|2013|32

Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation

|Virus Research|2013|31

CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR <sup>−/−</sup> Mice

|Journal of Virology|2018|27

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus

|Vaccines|2020|26